Abstract
Background To define the frequency of respiratory community-acquired bacterial co-infection in patients with coronavirus disease 2019 (COVID-19) based on a complete clinical assessment, including prior antibiotic use, clinical characteristics, inflammatory markers, chest computed tomography (CT) results and microbiological test results.
Methods This study was conducted within a cohort of prospectively included patients admitted for COVID-19 in our tertiary medical centres between 1-3-2020 and 1-6-2020. A multidisciplinary study team developed a diagnostic protocol to retrospectively categorize patients as unlikely, possible or probable bacterial co-infection based on clinical, radiological and microbiological parameters in the first 72 hours of admission. Within the three categories, we summarized patient characteristics and antibiotic consumption.
Results Among 281 included COVID-19 patients, bacterial co-infection was classified as unlikely in 233 patients (82.9%), possible in 35 patients (12.4%) and probable in 3 patients (1.1%). Ten patients (3.6%) could not be classified due to inconclusive data. Within 72 hours of hospital admission, 81% of the total study population and 78% of patients classified as unlikely bacterial co-infection received antibiotics.
Conclusions COVID-19 patients are unlikely to have a respiratory community-acquired bacterial co-infection. Prospective studies should define the safety of restrictive antibiotic use in COVID-19 patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No financial support was used for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data for this cohort was prospectively gathered from electronic health records according to the case report form (CRF) designed by the World Health Organization (WHO, (14)). This study was approved by the Medical Ethics Committee VUmc (Amsterdam, the Netherlands); All necessary patient consent has been obtained and archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Both Sophie Coenen and Jara R. de la Court have full access to the data used for this manuscript. The data that support the findings of this study are available from the corresponding author, upon reasonable request.
ABBREVIATIONS
- (COVID-19)
- coronavirus disease 2019
- (CT)
- computed tomography
- (CAP)
- community-acquired pneumonia
- (CRF)
- case report form
- (WHO)
- World Health Organization
- (CO-RADS)
- COVID-19 Reporting and Data System
- (CRP)
- C-reactive protein
- (BAL)
- bronchoalveolar lavage
- (IQR)
- interquartile range
- (DOTs)
- days of therapy
- (PCT)
- procalcitonin